14 Best Long Term Growth Stocks to Buy Now

10. DexCom, Inc. (NASDAQ:DXCM)

5-year EPS Growth: ~21.5%

Projected 5-year EPS Growth: ~25.5%

Number of Hedge Fund Holders: 60

DexCom, Inc. (NASDAQ:DXCM) is one of the Best Long Term Growth Stocks to Buy Now. On September 19, William Blair analyst Brandon Vazquez maintained their bullish stance on the company’s stock, giving a “Buy” rating. The analyst’s rating is backed by a combination of factors demonstrating its growth potential despite current concerns. The analyst noted that the MAUDE database, which raised some quality issues, is noisy and not definitive, as it allows anyone to file reports that are not always verified. The analyst highlighted the importance of analyzing such filings amidst strong growth in DexCom, Inc. (NASDAQ:DXCM)’s user base, providing a clearer picture of the situation.

Also, the analyst emphasized that the recent trends in MAUDE filings remain in line with DexCom, Inc. (NASDAQ:DXCM)’s explanations, demonstrating that the company addressed the issues effectively.  During Q2 2025, the company delivered healthy revenue results, presented compelling clinical data at ADA, and further advocated for expanded coverage in critical growth markets. In H2 2025, the company remains focused on continuing its commercial momentum while, at the same time, advancing its product portfolio amidst the highly anticipated launch of the Dexcom G7 15 Day System.

Sands Capital, an investment management company, released its Q4 2024 investor letter. Here is what the fund said:

“DexCom, Inc. (NASDAQ:DXCM) was a significant detractor from absolute and relative results in 2024, which we attribute to a combination of poor execution and fears of disruption by GLP-1 drugs.

The business’ second-quarter 2024 results were surprisingly weak, as a disruptive sales force reorganization and a rapid shift of patients to lower priced channels pressured volumes, revenues, and earnings. This poor execution worsened existential concerns about Dexcom’s addressable market, with GLP-1s viewed as potentially reducing the number of diabetics globally.

Third-quarter results demonstrated operational improvement. The chief commercial officer responsible for the disruptive reorganization was removed, Dexcom reported a record quarter for new patient additions, and volume growth exceeded 20 percent year-over-year. Additionally, Dexcom submitted its 15-day device to the U.S. Food and Drug Administration for approval six months earlier than expected…” (Click here to read the full text)